The Medicare GLP-1 Bridge is a temporary federal program that runs from July 1, 2026 through December 31, 2027. It lets eligible Medicare Part D members get certain GLP-1 weight-loss medications — Wegovy, the Zepbound KwikPen, or Foundayo — for a flat $50 per month. Below is a plain-English breakdown of what it covers, who qualifies, what it really costs, and what your options are if the Bridge is not a fit for you.
Key Takeaways
- The Bridge is a temporary CMS program (July 1, 2026 – December 31, 2027) offering Wegovy, the Zepbound KwikPen, or Foundayo for a flat $50 per month to eligible Medicare Part D members.
- Eligibility requires Part D enrollment, a qualifying BMI, and a prior authorization submitted to a central CMS processor.
- The $50 copay does not count toward your Part D deductible or yearly out-of-pocket cap, and the low-income Extra Help subsidy cannot be applied to it.
- Ozempic and Mounjaro are not included — the Bridge covers medications carrying a weight-loss indication only.
- If you are under 65, not enrolled in Part D, or below the BMI thresholds, physician-supervised, cash-pay weight-loss care remains an option.
What is the Medicare GLP-1 Bridge?
For years, Medicare did not cover GLP-1 medications when they were prescribed purely for weight loss — coverage was limited to people using them for conditions like type 2 diabetes or cardiovascular disease. The Medicare GLP-1 Bridge, launched by the Centers for Medicare & Medicaid Services (CMS) on July 1, 2026, changes that for a defined window of time. It is structured as a short-term demonstration program running through December 31, 2027, designed to expand access while a longer-term Medicare approach is developed.
Because it operates outside the normal Part D benefit, the program has its own rules — including a fixed copay and a separate prior-authorization process — that are worth understanding before you talk with your provider.
Which medications are covered?
The Bridge covers three weight-loss medications:
- Wegovy (semaglutide) — both the weekly injection and the daily tablet.
- Zepbound KwikPen (tirzepatide) — the KwikPen formulation only; single-dose pens and vials are not covered.
- Foundayo (orforglipron) — a daily oral GLP-1 tablet.
Two drugs people often ask about — Ozempic and Mounjaro — are not part of the Bridge, because they carry a diabetes indication rather than a weight-loss one. Coverage for those still depends on your individual Part D plan’s formulary.
Who qualifies?
To use the Bridge, you generally need to meet all of the following:
- Active enrollment in a Medicare Part D plan — either a standalone Prescription Drug Plan or a Medicare Advantage plan that includes drug coverage.
- A qualifying body mass index: 35 or higher; or 30 or higher with a condition such as heart failure, uncontrolled high blood pressure, or chronic kidney disease; or 27 or higher with a condition such as pre-diabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease.
- A prior authorization submitted by your prescriber to a central CMS processor — not to your individual plan.
That last point is new for many providers: the prior authorization goes to a single central processor set up specifically for the Bridge, which can add a step to the timeline. If you are already taking a GLP-1, your prescriber can attest that you met the clinical criteria when you first started therapy.
What does it actually cost?
The headline number is a flat $50 per month, regardless of your income level or the dose you are prescribed. That is a meaningful change from typical cash prices, which have run anywhere from roughly $150 to $700 or more per month depending on the drug and dose. A few caveats matter, though:
- The $50 copay does not count toward your Part D deductible or your yearly out-of-pocket maximum.
- The low-income Extra Help subsidy cannot be applied to Bridge prescriptions.
- Additional manufacturer coupons or discounts cannot be stacked to lower the $50 further.
For eligible members, it is still a substantial saving — just one that sits outside your normal Part D math.
How long does it last?
The Bridge is scheduled to run only through December 31, 2027. It is meant to “bridge” the gap until a longer-term Medicare approach is decided, and there is no guaranteed successor in place yet. That timeline matters clinically: research on GLP-1 therapy consistently shows that many people regain a meaningful portion of lost weight within about a year of stopping. If you start on the Bridge, it is worth planning early — with your provider — for what maintenance looks like when the program ends.
What if you don’t qualify — or you’re not on Medicare?
The Bridge is built for a specific group: Medicare Part D members who meet the clinical criteria. That leaves a lot of people out — anyone under 65, anyone without Part D coverage, and anyone whose BMI or health profile does not meet the thresholds. If that is you, physician-supervised weight-loss care is still very much available.
At Evolve Health & Wellness, our medical weight-loss program is built around your labs, not a brochure. For patients who qualify, we prescribe GLP-1 medications like semaglutide and tirzepatide, and we monitor the things that actually drive results — metabolic markers, body composition, and how your body responds over time. In the SURMOUNT-5 head-to-head trial, tirzepatide produced greater average weight loss than semaglutide over 72 weeks, but the right medication and dose is an individual decision your provider makes with you, not a one-size-fits-all answer.
To be clear: Evolve is not affiliated with, and is not a provider of, the Medicare GLP-1 Bridge. This article is educational. For questions about your Bridge eligibility, talk with your prescriber or call 1-800-MEDICARE.
Not eligible for the Bridge? You still have options.
Our providers can walk you through a personalized, physician-supervised plan — labs, medication if appropriate, and ongoing monitoring. Book a weight-loss consultation at evolvehealthfl.com/weight-loss or call (407) 593-1372.
Individual results may vary. All medications are prescribed and monitored by licensed medical providers.
